"description","rationale","instanceType","name","uuid:ID","label","id"
"The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","Study Design 1","2d359517-9b6f-4e29-802c-12a8a2d0d584","","StudyDesign_1"
